Skip to content

Postoperative Biliary Fistula Prevention After Hepatectomy

Postoperative Biliary Fistula Prevention After Hepatectomy by External Biliary Duct Stent:Prospective Multicenter Randomized Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01469442
Acronym
VPI
Enrollment
304
Registered
2011-11-10
Start date
2009-05-01
Completion date
2017-09-01
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatectomy

Keywords

Biliary fistula, prevention, hepatectomy, external stent, Hepatectomy of more 2 segments, Not emergency or laparoscopy surgery

Brief summary

Aim : Effect of external biliary duct stent after hepatectomy on the occurence of postoperative biliary fistula. Methods : French prospective multicenter randomized trial. Population study: Adult patients who underwent hepatectomy (\> 2 segments) on non-cirrhotic liver. Hypothesis: decreased postoperative biliary fistula from 15% to 5% with the presence of a external biliary duct stent. With this hypothesis, the number of patients required to be equal to 152 per group for a total of 304 patients. Outcome measure: Primary : Postoperative biliary complications (biliary fistula, biloma, biliary peritonitis) Secondary : All morbidity, mortality, additional manoeuvres to treat biliary fistula, during of hospital stay and biliary fistula. Follow up: A follow-up of patients 3 months after surgery for all patients. The planned total duration of the study is 3 years and 3 months.

Detailed description

After performing the hepatectomy and verification of hemostasis, patients were randomized (external biliary duct stent or not) by sealed envelopes. Systematic intraoperative test with methylene blue or air by the external biliary duct stent (EBDS) will necessary for all patients. Intra-abdominal drainage or not and type will be at the discretion of the surgeon. The EBDS will be left open for the first 7 postoperative days and then clamped. The EBDS will be removed during a consultation 5 weeks after surgery. Both groups of patients will be reviewed at 3 months after surgery, it will be noted at this point the possible complications related to the presence of EBDS (leakage from the drain, drop..). If patients are hospitalized more than five weeks, the study will stop at their consultation three months or the day of the consultation where the DTC is removed if it is still present at 3 months.

Interventions

PROCEDUREExternal Biliary duct stent in the bile duct by cystic way

The size of the external biliary duct stent depending of cystic duct size

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject has given his informed consent and signed consent * Hepatectomy at least 2 segments of liver parenchyma for a benign or malignant disease by laparotomy * Not cirrhotic liver

Exclusion criteria

* Surgery made in emergency * Surgery by laparoscopy * Need to draw up a bilic-digestive anastomosis * Liver cirrhosis * History of cholecystectomy * Resection of less than 2 segments * Preoperative jaundice (total bilirubin\> 30 micromol / l) * Presence of preoperative biliary drainage * Patients requiring the installation of a drain transcystic during the operation

Design outcomes

Primary

MeasureTime frameDescription
Postoperative biliary fistula3 months after surgey3 forms of diagnosis : bile in the intra-abdominal drainage; presence of an intra-abdominal collection of bile liquid (biloma); presence of an effusion of bile in the abdominal space (biliary peritonitis).

Secondary

MeasureTime frameDescription
Morbidity3 months after surgeyadditional maneuvers for treat biliary fistula, during of hospital stay, during of biliary fistula
Mortality3 months after surgery

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFabrice MUSCARI, MD

University Hospital, Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026